ストックスクリーナーアプリを入手
5.50
2.83%
-0.16
前日終値:
$5.66
開ける：
$5.74
24時間の取引高:
1.06M
Relative Volume:
1.24
時価総額：
$408.34M
収益：
-
当期純損益:
$-96.66M
株価収益率:
-2.5581
EPS:
-2.15
ネットキャッシュフロー:
$-83.73M
1週間 パフォーマンス:
+7.00%
1か月 パフォーマンス:
-9.84%
6か月 パフォーマンス:
-61.57%
1年 パフォーマンス:
-51.24%
1日の値動き範囲:
$5.49
$5.93
1週間の範囲:
$5.16
$5.93
52週間の値動き範囲:
$4.60
$16.77
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
名前
Olema Pharmaceuticals Inc
セクター
電話
(415) 651-3316
住所
780 BRANNAN STREET, SAN FRANCISCO
OLMA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
5.50 | 408.34M | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-02 | 開始されました | Goldman | Buy |
| 2024-01-30 | 開始されました | Citigroup | Buy |
| 2023-07-21 | 開始されました | Oppenheimer | Outperform |
| 2023-05-05 | 開始されました | CapitalOne | Overweight |
| 2023-02-22 | 開始されました | Credit Suisse | Outperform |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-06-09 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | 開始されました | H.C. Wainwright | Neutral |
| 2021-12-07 | 再開されました | Cowen | Outperform |
| 2020-12-14 | 開始されました | Canaccord Genuity | Buy |
| 2020-12-14 | 開始されました | Cowen | Outperform |
| 2020-12-14 | 開始されました | JP Morgan | Overweight |
| 2020-12-14 | 開始されました | Jefferies | Buy |
すべてを表示
Olema Pharmaceuticals Inc (OLMA) 最新ニュース
JPMorgan Chase & Co. Buys 157,171 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock Holdings Increased by Hennion & Walsh Asset Management Inc. - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives $27.00 Consensus Target Price from Brokerages - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Form 424B5 Olema Pharmaceuticals, - StreetInsider.com
Barclays PLC Purchases 48,614 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Bain Capital Life Sciences Investors, LLC Acquires Significant Stake in Olema Pharmaceuticals Inc - GuruFocus.com
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Major Shareholder Acquires $1,728,000.00 in Stock - MarketBeat
Bain Capital Life Sciences buys $1.7m in Olema Pharmaceuticals stock - Investing.com Nigeria
Olema Pharmaceuticals announces equity security exchange By Investing.com - Investing.com Australia
Olema Pharmaceuticals announces equity security exchange - Investing.com India
Olema Pharmaceuticals stock hits 52-week low at $5.02 - Investing.com India
Olema Pharmaceuticals stock hits 52-week low at $5.02 By Investing.com - Investing.com South Africa
(OLMA) Investment Report - Stock Traders Daily
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Pharmaceuticals Awards New Employee Stock Options for Cancer Drug Development Team - StockTitan
Olema Pharmaceuticals stock hits 52-week low at $5.55 By Investing.com - Investing.com Australia
Olema Pharmaceuticals stock hits 52-week low at $5.55 - Investing.com India
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Geode Capital Management LLC Decreases Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Geode Capital Management LLC Sells 125,170 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Barclays PLC Acquires 48,614 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Oncology Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateForm 8-K - Marketscreener.com
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion - MSN
State Street Corp Boosts Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Rating of “Buy” by Brokerages - Defense World
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Rating of "Buy" by Brokerages - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 7,616 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
Olema Pharmaceuticals director Graham Walmsley sells $4.73m in stock By Investing.com - Investing.com Australia
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $4,730,136.75 in Stock - MarketBeat
Olema Pharmaceuticals director Graham Walmsley sells $4.73m in stock - Investing.com
(OLMA) Technical Pivots with Risk Controls - Stock Traders Daily
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Bought by Wellington Management Group LLP - MarketBeat
Charles Schwab Investment Management Inc. Increases Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Charles Schwab Investment Management Inc. Buys 207,565 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
What is HC Wainwright’s Forecast for OLMA FY2024 Earnings? - Defense World
What is HC Wainwright's Estimate for OLMA FY2024 Earnings? - MarketBeat
Olema Pharmaceuticals stock hits 52-week low at $7.67 By Investing.com - Investing.com Canada
Olema Pharmaceuticals stock hits 52-week low at $7.67 - Investing.com India
Olema Pharmaceuticals CEO Sean Bohen sells shares worth $986,365 By Investing.com - Investing.com Nigeria
Olema Pharmaceuticals, Inc. announced that it has received $249.999225 million in funding from a group of investors - Marketscreener.com
Olema Pharmaceuticals director sells shares worth $147,955 By Investing.com - Investing.com Nigeria
Olema Pharmaceuticals CEO Sean Bohen sells shares worth $986,365 - Investing.com
Olema Pharmaceuticals Inc (OLMA) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):